Calquence (acalabrutinib; AstraZeneca/Acerta) Markets, 2017-2026: A Novel, Orally Available, Second-Generation Bruton's Tyrosine Kinase Inhibitor with Potential Antineoplastic Activity

By In The News
July 8, 2019 in The Headlines

Recommended Posts

In The News

Posted July 8, 2019

- Share

Posted July 8, 2019

DUBLIN, July 8, 2019 /PRNewswire/ -- The "Calquence" report has been added to ResearchAndMarkets.com's offering. Calquence (acalabrutinib; AstraZeneca/Acerta) is a novel, orally available, second-generation Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity....

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  221944
2. Jaydee
  17740
3. deicer
  13314
4. Kip Powick
  12306
5. dagger
  9614
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  272.3k
- Total Posts
  
  564.8k

Sign In

Calquence (acalabrutinib; AstraZeneca/Acerta) Markets, 2017-2026: A Novel, Orally Available, Second-Generation Bruton's Tyrosine Kinase Inhibitor with Potential Antineoplastic Activity

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support